Comparative study of low dose of capecitabine versus standard dose in metastatic breast cancer: Efficacy and safety

[1] Diasio RB. An evolving role for oral fluoropyrimidine drugs. J Clin Oncol 2002; 20: 894–896. DiasioRB An evolving role for oral fluoropyrimidine drugs J Clin Oncol 2002 20 894 896 10.1200/JCO.2002.20.4.894 Search in Google Scholar

[2] Schuller J, Cassidy J, Dumont E, et al. Preferential activation of capecitabine in tumor following oral administration in colorectal cancer patients. Cancer Chemother Pharmacol 2000; 45: 291–297. SchullerJ CassidyJ DumontE Preferential activation of capecitabine in tumor following oral administration in colorectal cancer patients Cancer Chemother Pharmacol 2000 45 291 297 10.1007/s002800050043 Search in Google Scholar

[3] Miwa M, Ura M, Nishida M, et al. Design of a novel oral fluoropyrimidine carbamate, capecitabine, which generates 5-fluorouracil selectively in tumours by enzymes concentrated in human liver and cancer tissue. Eur J Cancer 1998; 34: 1274–1281. MiwaM UraM NishidaM Design of a novel oral fluoropyrimidine carbamate, capecitabine, which generates 5-fluorouracil selectively in tumours by enzymes concentrated in human liver and cancer tissue Eur J Cancer 1998 34 1274 1281 10.1016/S0959-8049(98)00058-6 Search in Google Scholar

[4] Twelves C. Vision of the future: Capecitabine. Oncologist 2001; 6 (Suppl 4): 35–39. TwelvesC Vision of the future: Capecitabine Oncologist 2001 6 Suppl 4 35 39 10.1634/theoncologist.6-suppl_4-35 Search in Google Scholar

[5] Cassidy J, Twelves C, Van Cutsem E, et al. First-line oral capecitabine therapy in metastatic colorectal cancer: A favorable safety profile compared with intravenous 5-fluorouracil/leucovorin. Ann Oncol 2002; 13: 566–575. CassidyJ TwelvesC Van CutsemE First-line oral capecitabine therapy in metastatic colorectal cancer: A favorable safety profile compared with intravenous 5-fluorouracil/leucovorin Ann Oncol 2002 13 566 575 10.1093/annonc/mdf089 Search in Google Scholar

[6] Fumoleau P, Largillier R, Trillet-Lenoir V, et al. Capecitabine (Xeloda) in patients with advanced breast cancer (ABC), previously treated with anthracyclines and taxanes: a large Phase II study. Proc Am Soc Clin Oncol 2002; 21:62 FumoleauP LargillierR Trillet-LenoirV Capecitabine (Xeloda) in patients with advanced breast cancer (ABC), previously treated with anthracyclines and taxanes: a large Phase II study Proc Am Soc Clin Oncol 2002 21 62 Search in Google Scholar

[7] O’Shaughnessy J, Blum J, Moiseyenko V, et al. Randomized, open label, phase II trial of oral capecitabine (Xeloda) vs. a reference arm of intravenous CMF (cyclophosphamide, methotrexate and 5-fluorouracil) as first-line therapy for advanced/metastatic breast cancer. Ann Oncol 2001; 12: 1247–1254. O’ShaughnessyJ BlumJ MoiseyenkoV Randomized, open label, phase II trial of oral capecitabine (Xeloda) vs. a reference arm of intravenous CMF (cyclophosphamide, methotrexate and 5-fluorouracil) as first-line therapy for advanced/metastatic breast cancer Ann Oncol 2001 12 1247 1254 10.1023/A:1012281104865 Search in Google Scholar

[8] O’Shaughnessy J, Miles D, Vukelja S, et al. Superior survival with capecitabine plus docetaxel combination therapy in anthracycline pretreated patients with advanced breast cancer: Phase III trial results. J Clin Oncol 2002; 20: 2812–2823. O’ShaughnessyJ MilesD VukeljaS Superior survival with capecitabine plus docetaxel combination therapy in anthracycline pretreated patients with advanced breast cancer: Phase III trial results J Clin Oncol 2002 20 2812 2823 10.1200/JCO.2002.09.002 Search in Google Scholar

[9] Blum JL, Dieras V, Lo Russo PM et al. Multicenter, phase II study of capecitabine in taxane-pretreated metastatic breast carcinoma patients. Cancer 2001; 92: 1759–1768. BlumJL DierasV Lo RussoPM Multicenter, phase II study of capecitabine in taxane-pretreated metastatic breast carcinoma patients Cancer 2001 92 1759 1768 10.1002/1097-0142(20011001)92:7<1759::AID-CNCR1691>3.0.CO;2-A Search in Google Scholar

[10] Taguchi T, Nakayama T, Masuda N, Yoshidome K, et al. Study of low-dose capecitabine monotherapy for metastatic breast cancer. Chemotherapy 2010; 56(2):166–170. TaguchiT NakayamaT MasudaN YoshidomeK Study of low-dose capecitabine monotherapy for metastatic breast cancer Chemotherapy 2010 56 2 166 170 10.1159/000313531 Search in Google Scholar

[11] Ambros T, Zeichner SB, Zaravinos J, Montero AJ, Ahn E, Aruna M, et al. A retrospective study evaluating a fixed low dose capecitabine monotherapy in women with HER-2 negative metastatic breast cancer. Breast Cancer Res Treat 2014;146(1):7–14. AmbrosT ZeichnerSB ZaravinosJ MonteroAJ AhnE ArunaM A retrospective study evaluating a fixed low dose capecitabine monotherapy in women with HER-2 negative metastatic breast cancer Breast Cancer Res Treat 2014 146 1 7 14 10.1007/s10549-014-3003-x Search in Google Scholar

[12] Bertelsen C, Ji L, Garcia A, Russell C, et al. Efficacy of Very-Low-Dose Capecitabine in Metastatic breast Cancer. Am J Hematol 2014; 11(2):20–30 BertelsenC JiL GarciaA RussellC Efficacy of Very-Low-Dose Capecitabine in Metastatic breast Cancer Am J Hematol 2014 11 2 20 30 Search in Google Scholar

[13] Nishijima T, Suzuki M, Hyman B. A comparison of toxicity profiles between the lower and standard dose capecitabine in breast cancer: a systematic review and meta-analysis. Breast Cancer Res Treat 2016 April ; 156(2): 227–236. NishijimaT SuzukiM HymanB A comparison of toxicity profiles between the lower and standard dose capecitabine in breast cancer: a systematic review and meta-analysis Breast Cancer Res Treat 2016 April 156 2 227 236 10.1007/s10549-016-3756-5498883126988358 Search in Google Scholar

[14] Rudek M, Connolly R, Hoskins J, Mayer E, et al. Fixed dose capecitabine is feasible: results from a pharmacokinetic and pharmacogenetic study in metastatic breast cancer. Breast Cancer Res Treat 2013 May; 139(1): 135–143. RudekM ConnollyR HoskinsJ MayerE Fixed dose capecitabine is feasible: results from a pharmacokinetic and pharmacogenetic study in metastatic breast cancer Breast Cancer Res Treat 2013 May 139 1 135 143 10.1007/s10549-013-2516-z367330023588952 Search in Google Scholar

[15] Koedoot CG, De Haes JC, Heisterkamp SH, Bakker PJ, et al. Palliative chemotherapy or watchful waiting? A vignettes study among oncologists. J Clin Oncol 2002;20(17):3658–3664. KoedootCG De HaesJC HeisterkampSH BakkerPJ Palliative chemotherapy or watchful waiting? A vignettes study among oncologists J Clin Oncol 2002 20 17 3658 3664 10.1200/JCO.2002.12.01212202667 Search in Google Scholar

[16] Rossi D, Alessandroni P, Catalano V et al. Safety profile and activity of lower capecitabine dose in patients with metastatic breast cancer. Clin Breast Cancer 2007; 7(11): 857–860. RossiD AlessandroniP CatalanoV Safety profile and activity of lower capecitabine dose in patients with metastatic breast cancer Clin Breast Cancer 2007 7 11 857 860 10.3816/CBC.2007.n.05018269775 Search in Google Scholar

[17] Kawaguchi T, Iwase S, Takeuchi H, et al. Chemotherapy with low-dose capecitabine as palliative treatment in a patient with metastatic breast cancer: a case report. Cases J 2009;2:9081. KawaguchiT IwaseS TakeuchiH Chemotherapy with low-dose capecitabine as palliative treatment in a patient with metastatic breast cancer: a case report Cases J 2009 2 9081 10.1186/1757-1626-2-9081280387820062718 Search in Google Scholar

[18] Blum JL, Jones SE, Buzdar AU, et al. Multicenter phase II study of capecitabine in paclitaxel-refractory metastatic breast cancer. J Clin Oncol 1999; 17(2): 485–493. BlumJL JonesSE BuzdarAU Multicenter phase II study of capecitabine in paclitaxel-refractory metastatic breast cancer J Clin Oncol 1999 17 2 485 493 10.1200/JCO.1999.17.2.48510080589 Search in Google Scholar

[19] Van Cutsem E, Findlay M, Osterwalder B, et al. Capecitabine, an oral fluoropyrimidine carbamate with substantial activity in advanced colorectal cancer: results of a randomized phase II study. J Clin Oncol 2000; 18(6): 1337–1345. Van CutsemE FindlayM OsterwalderB Capecitabine, an oral fluoropyrimidine carbamate with substantial activity in advanced colorectal cancer: results of a randomized phase II study J Clin Oncol 2000 18 6 1337 1345 10.1200/JCO.2000.18.6.133710715306 Search in Google Scholar

[20] Haller DG, Cassidy J, Clarke SJ, et al. Potential regional differences for the tolerability profiles of fluoropyrimidines. J Clin Oncol 2008; 26(13): 2118–2123. HallerDG CassidyJ ClarkeSJ Potential regional differences for the tolerability profiles of fluoropyrimidines J Clin Oncol 2008 26 13 2118 2123 10.1200/JCO.2007.15.209018445840 Search in Google Scholar

[21] Sezgin C, Kurt E, Evrensel T et al. Efficacy of lower dose capecitabine in patients with metastatic breast cancer and factors influencing therapeutic response and outcome. South Med J 2007; 100(1): 27–32. SezginC KurtE EvrenselT Efficacy of lower dose capecitabine in patients with metastatic breast cancer and factors influencing therapeutic response and outcome South Med J 2007 100 1 27 32 10.1097/01.smj.0000252968.87824.1917269522 Search in Google Scholar

[22] Hennessy B, Gauthier A, Michaud L, Hortobagyi G, et al Lower dose capecitabine has a more favorable therapeutic index in metastatic breast cancer: retrospective analysis of patients treated at M. D. Anderson Cancer Center and a review of capecitabine toxicity in the literature. Ann Oncol 2005; 16: 1289–1296. HennessyB GauthierA MichaudL HortobagyiG Lower dose capecitabine has a more favorable therapeutic index in metastatic breast cancer: retrospective analysis of patients treated at M.D. Anderson Cancer Center and a review of capecitabine toxicity in the literature Ann Oncol 2005 16 1289 1296 10.1093/annonc/mdi25315890665 Search in Google Scholar

[23] Cassidy J, Twelves C, Van Cutsem E, et al. First-line oral capecitabine therapy in metastatic colorectal cancer: A favorable safety profile compared with intravenous 5-fluorouracil/leucovorin. Ann Oncol 2002; 13: 566–575. CassidyJ TwelvesC Van CutsemE First-line oral capecitabine therapy in metastatic colorectal cancer: A favorable safety profile compared with intravenous 5-fluorouracil/leucovorin Ann Oncol 2002 13 566 575 10.1093/annonc/mdf08912056707 Search in Google Scholar

[24] Zielinski C, Gralow J, Martin M. Optimizing the dose of capecitabine in metastatic breast cancer: confused, clarified or confirmed? Ann Oncol 2010; 21: 2145–2152. ZielinskiC GralowJ MartinM Optimizing the dose of capecitabine in metastatic breast cancer: confused, clarified or confirmed? Ann Oncol 2010 21 2145 2152 10.1093/annonc/mdq06920332132 Search in Google Scholar

[25] Hoff PM, Ansari R, Batist G, et al. Comparison of oral capecitabine (Xeloda) v intravenous 5-fluorouracil plus leucovorin (Mayo Clinic regimen) as first-line treatment in 605 patients with metastatic colorectal cancer: Results of a randomized phase III study. J Clin Oncol 2001; 19: 2282–2292. HoffPM AnsariR BatistG Comparison of oral capecitabine (Xeloda) v intravenous 5-fluorouracil plus leucovorin (Mayo Clinic regimen) as first-line treatment in 605 patients with metastatic colorectal cancer: Results of a randomized phase III study J Clin Oncol 2001 19 2282 2292 10.1200/JCO.2001.19.8.228211304782 Search in Google Scholar

[26] Talbot DC, Moiseyenko V, Van Belle S, et al. Randomised, phase II trial comparing oral capecitabine (Xeloda) with paclitaxel in patients with metastatic/advanced breast cancer pretreated with anthracyclines. Br J Cancer 2002; 86: 1367–1372. TalbotDC MoiseyenkoV Van BelleS Randomised, phase II trial comparing oral capecitabine (Xeloda) with paclitaxel in patients with metastatic/advanced breast cancer pretreated with anthracyclines Br J Cancer 2002 86 1367 1372 10.1038/sj.bjc.6600261237538411986765 Search in Google Scholar

[27] Harbeck N, Saupe S, Jäger E, Schmidt M, et al. A randomized phase III study evaluating pegylated liposomal doxorubicin versus capecitabine as first-line therapy for metastatic breast cancer: Results of the PELICAN study. Breast Cancer Res Treat 2017;161(1):63–72. HarbeckN SaupeS JägerE SchmidtM A randomized phase III study evaluating pegylated liposomal doxorubicin versus capecitabine as first-line therapy for metastatic breast cancer: Results of the PELICAN study Breast Cancer Res Treat 2017 161 1 63 72 10.1007/s10549-016-4033-3522291527798749 Search in Google Scholar

[28] Robert NJ, Dieras V, Glaspy J, Brufsky AM, Bondarenko I, Lipatov ON, et al. RIBBON-1: randomized, double-blind, placebo-controlled, phase III trial of chemotherapy with or without bevacizumab for first-line treatment of human epidermal growth factor receptor 2-negative, locally recurrent or metastatic breast cancer. J Clin Oncol 2011; 29(10):1252–1260. RobertNJ DierasV GlaspyJ BrufskyAM BondarenkoI LipatovON RIBBON-1: randomized, double-blind, placebo-controlled, phase III trial of chemotherapy with or without bevacizumab for first-line treatment of human epidermal growth factor receptor 2-negative, locally recurrent or metastatic breast cancer J Clin Oncol 2011 29 10 1252 1260 10.1200/JCO.2010.28.098221383283 Search in Google Scholar

[29] Stockler MR, Harvey VJ, Francis PA, Byrne MJ, Ackland SP, Fitzharris B, et al. Capecitabine versus classical cyclophosphamide, methotrexate, and fluorouracil as first-line chemotherapy for advanced breast cancer. J Clin Oncol 2011; 29(34):4498–4504. StocklerMR HarveyVJ FrancisPA ByrneMJ AcklandSP FitzharrisB Capecitabine versus classical cyclophosphamide, methotrexate, and fluorouracil as first-line chemotherapy for advanced breast cancer J Clin Oncol 2011 29 34 4498 4504 10.1200/JCO.2010.33.910122025143 Search in Google Scholar

[30] Debled M, Madranges N, Trainaud A, et al. First-line capecitabine monotherapy for slowly progressing metastatic breast cancer: do we need aggressive treatment? Oncology 2009; 77: 318–327. DebledM MadrangesN TrainaudA First-line capecitabine monotherapy for slowly progressing metastatic breast cancer: do we need aggressive treatment? Oncology 2009 77 318 327 10.1159/00026090419940523 Search in Google Scholar

[31] Bajetta E, Procopio G, Celio L, et al. Safety and efficacy of two different doses of capecitabine in the treatment of advanced breast cancer in older women. J Clin Oncol 2005; 23(10): 2155–2161. BajettaE ProcopioG CelioL Safety and efficacy of two different doses of capecitabine in the treatment of advanced breast cancer in older women J Clin Oncol 2005 23 10 2155 2161 10.1200/JCO.2005.02.16715710946 Search in Google Scholar